COVID-19 Where do we stand?


Dr Adrian Hyzler Chief Medical Officer

28th February 2022






Current Global Situation






Region of: Americas






Region of: Africa






Region of: Europe






Region of: Eastern Mediterranean






Region of: South East Asia





Region of: Western Pacific





Bloomberg 'Covid Resilience Ranking'


Covid Resilience Ranking

			Get info and sort on table headers 💲			
	← Worse	Better →	REOPENING PROGRESS COVID		D STATUS 🔻 QUALITY OF LIFE 🔻	
RANK CHANGE	ECONOMY	BLOOMBERG RESILIENCE SCORE	VACCINE DOSES PER 100	LOCKDOWN SEVERITY	FLIGHT CAPACI	VACCINATED TY TRAVEL ROUTES
1 -	UAE	76.2	259.1	44	-27.7	7% 412
2 48	Ireland	75.5	211.5	23	-25.3	3% 411
3 💌 1	Saudi Arabia	74.1	172.5	49	-20.3	3% 389
4 ▲7	Norway	72.8	208.1	25	- 33	3% 411.5
5 4 2	Australia	71.7	208	44	- 47.8	3% 408
6 47	Spain	69.2	204	49	-24.1	1% 412.5
7 •4	Finland	67.9	206.8	42	-51.8	3% 412.5
8 ▲11	Colombia	66.8	151.3	59	16.4	405.5
9 🔺 3	U.K.	66.8	208	42	-41.3	3% 412
10 ▲11	Portugal	66	224	14	-19.6	5% 230
11 ▲21	Denmark	65.8	226	17	- 42.4	412.5
12 1 8	Belgium	65.4	215.5	47	-37.1	1% 411.5
13 🔺 1	Canada	65.2	212.7	69	- 47.7	409.5
14 ▲8	Switzerland	64.7	180.5	56	-39.4	412.5
15 🔻 9	Chile	64.7	247.2	30	- 17	7% 285
16 1 0	France	64.4	219.3	64	-27.8	3% 412
17 ▲32	Argentina	64.3	203.9	37	-41.7	7% 405
18 ▼1 4	Turkey	64	173.6	62	-23.2	2% 407.5
19 🔺 8	Malaysia	63.8	201.7	54	- 55.7	7% 397
20 🔺 3	U.S.	63.2	167.1	59	-8.8	3% 413.5

Bloomberg Resilience Ranking as of Feb 23 2022



'The rise and fall of Omicron'




Year and week of specimen collection

Omicron peaked in the first week of January 2022



The Omicron surge






What do we know about Omicron?


Omicron is the 5th 'variant of concern' on the WHO database, first identified in South Africa in November 2021

- An umbrella term for a number of variants
- Omicron has rapidly replaced Delta
- Omicron BA.1 is being displaced by Omicron BA.2
- BA.2 is at least 30% more transmissible than BA.1
- BA.2 can evade immunity better than BA.1
- Current monoclonal antibodies are ineffective
- Omicron appears to be 75% less virulent than Delta, but equal to the ancestral SARS-CoV-2
- Because of the size of the BA.1 surge it seems that BA.2 may prolong the surge but not spark a second major wave





Tools to control the spread







Vaccination and boosters

COVID-19 vaccine initial doses and boosters per 100 people, Feb 24, 2022 Total number of doses administered, broken down by whether they are part of the initial protocol or booster doses, divided by the total population of the country. Our World in Data

Initial protocol doses Booster doses







How do we transition from pandemic to endemic?

A disease becomes endemic when it reaches a predictable state.



Protect lives and livelihoods



Ensure ongoing surveillance data

Develop next-gen vaccines & treatments



Protect health service infrastructure



Continue public health messaging



What potential dangers lie ahead?



New variants

Could cause:

- Testing to be ineffective
- Vaccines to become less effective
- Treatments to become less effective
- More severe disease
- Increased transmissibility

9

Long COVID

Increasing evidence that a significant number of people will continue to suffer symptoms long after their initial infection



The next pandemic

Another pandemic could arise and take the world by surprise

What do we know about Long Covid? healix

Data from the UK Office for National Statistics, January 2022

- Generally accepted definition of ongoing symptoms >12 weeks
- An estimated 1.3 million living with Long Covid in UK (2.0% of population)
- 40% (506,000 people) ongoing for >1 year
- 64% (809,000) reported 'adversely affected day-to-day activities'
- 20% (247,000) reported ability to undertake day-to-day activities 'limited a lot'
- Fatigue most common symptom (51%) followed by loss of smell, shortness of breath and difficulty concentrating
- Most common in 35-69 year olds, females, deprived living, those working in healthcare, social care, teaching or education

STUDIES SHOW THAT VACCINATION REDUCES THE INCIDENCE OF LONG COVID BY UP TO 50%.





WHO Potential Future Scenarios

- Scenario One- the current COVID situation remains static with ongoing case numbers and steady mortality rates.
- Scenario Two- the pandemic transitions to an endemic state where COVID is considered like any other respiratory pathogen, similar to influenza for example, and we experience regular numbers of cases with seasonal peaks
- Scenario Three- new variants continue to emerge creating a similar situation to 2020 and we have to start all over again with newly developed vaccines, lockdowns and large numbers of hospitalisations and deaths, as well as devastating economic consequences.






Challenges for business travel

- Business trip vs video-conference?
- Can you identify 'safe' destinations?
- What restrictions exist for business travel?
- What is your vaccination policy?
- Who is safe to travel?
- Who wants to travel: 'never left'; never returning'; 'fear of missing out (FOMO)'; 'wait and see'? [McKinsey & Company]





Healix COVID Travel Safe



Three risk factors

COVID Travel Safe assesses risk factors associated with the country, medical and logistical risk context. Each of these categories is assigned a rating which informs an overall assessment of the risk environment

The medical questionnaire

Alongside the medical context, our medical experts have also developed an in-house tool that calculates the risk of developing complications from COVID-19 based on a travellers personal medical history

Behind the scenes

Our team are closely monitoring the science, government restrictions and logistical issues around the world, ensuring the information driving COVID Travel Safe is representative of the pandemic's evolution

Key message...

All pandemics come to an end, and so will this one

Questions?

Visit our website www.healix.com

Contact us Javier.Ruz-Bentue@healix.com +34 647 820333

jpn@healix.com +44 7710 097499

